|
Secondary prevention
Citations 11-20 of 240 total displayed.
|
Past content
(since Jun 2001):
|
- Research Letters
Sarpogrelate Versus Aspirin in Secondary Prevention of Cerebral Infarction: Differential Efficacy in Diabetes?: Subgroup Analysis From S-ACCESS
- Yukito Shinohara, Katsuya Nishimaru for the S-ACCESS study group
Stroke 2009;40:2862-2865; published online before print as doi:10.1161/STROKEAHA.109.554246
[Abstract]
[Full text]
- Articles
Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings. No
- Martin H. Strauss and Alistair Hall
Stroke published July 30, 2009, doi:10.1161/STROKEAHA.109.559062
[Abstract]
- Original Contributions
Lipoprotein-Associated Phospholipase A2 and C-Reactive Protein for Risk-Stratification of Patients With TIA
- Brett L. Cucchiara, Steve R. Messe, Lauren Sansing, Larami MacKenzie, Robert A. Taylor, James Pacelli, Qaisar Shah, and Scott E. Kasner
Stroke 2009;40:2332-2336; published online before print as doi:10.1161/STROKEAHA.109.553545
[Abstract]
[Full text]
- Original Contributions
Patent Foramen Ovale in Cryptogenic Stroke: Incidental or Pathogenic?
- Alawi A. Alsheikh-Ali, David E. Thaler, and David M. Kent
Stroke 2009;40:2349-2355; published online before print as doi:10.1161/STROKEAHA.109.547828
[Abstract]
[Full text]
- Original Contributions
Sample Size Estimates for Clinical Trials of Vasospasm in Subarachnoid Hemorrhage
- Kurt T. Kreiter, Stephan A. Mayer, George Howard, Volker Knappertz, Don Ilodigwe, Michael A. Sloan, and R. Loch Macdonald
Stroke 2009;40:2362-2367; published online before print as doi:10.1161/STROKEAHA.109.547331
[Abstract]
[Full text]
- Original Contributions
Relative and Cumulative Effects of Lipid and Blood Pressure Control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial
- Pierre Amarenco, Larry B. Goldstein, Michael Messig, Blair J. O'Neill, Alfred Callahan, III, Henrik Sillesen, Michael G. Hennerici, Justin A. Zivin, K.M.A. Welch on behalf of the SPARCL Investigators
Stroke 2009;40:2486-2492; published online before print as doi:10.1161/STROKEAHA.108.546135
[Abstract]
[Full text]
- Research Letters
Predictors of Smoking Abstinence After First-Ever Ischemic Stroke: A 3-Month Follow-Up
- Halina Sienkiewicz-Jarosz, Pawel Zatorski, Anna Baranowska, Danuta Ryglewicz, and Przemyslaw Bienkowski
Stroke 2009;40:2592-2593; published online before print as doi:10.1161/STROKEAHA.108.542191
[Abstract]
[Full text]
- Articles
Patients Enrolled in Large Randomized Clinical Trials of Antiplatelet Treatment for Prevention After Transient Ischemic Attack or Ischemic Stroke Are Not Representative of Patients in Clinical Practice. The Netherlands Stroke Survey
- Lisette Maasland, Robert J. van Oostenbrugge, Cees F. Franke, Wilma J.M. Scholte op Reimer, Peter J. Koudstaal, Diederik W.J. Dippel for the Netherlands Stroke Survey Investigators
Stroke published June 25, 2009, doi:10.1161/STROKEAHA.109.551812
[Abstract]
- Articles
Sarpogrelate Versus Aspirin in Secondary Prevention of Cerebral Infarction: Differential Efficacy in Diabetes? Subgroup Analysis From S-ACCESS
- Yukito Shinohara, Katsuya Nishimaru for the S-ACCESS study group
Stroke published June 11, 2009, doi:10.1161/STROKEAHA.109.554246
[Abstract]
- Research Letters
Ethnicity Does Not Affect the Homocysteine-Lowering Effect of B-Vitamin Therapy in Singaporean Stroke Patients
- Katherine Kasiman, John W. Eikelboom, Graeme J. Hankey, Samantha P.-K. Lee, Joanna P.-Z. Lim, Jasinda H.-Q. Lee, Hui-Meng Chang, Meng-Cheong Wong, and Christopher P.L.-H. Chen
Stroke 2009;40:2209-2211; published online before print as doi:10.1161/STROKEAHA.108.535237
[Abstract]
[Full text]
|
|
